Malaria vaccine(National Institute of Allergy & Infectious Diseases)(Malaria vaccine(National Institute of Allergy & Infectious Diseases))

概要

基本信息

药物类型

重组载体疫苗、预防性疫苗

别名

Malaria vaccine

靶点-

作用机制

免疫刺激剂

治疗领域

感染

在研适应症

疟疾

非在研适应症-

原研机构

National Institute of Allergy & Infectious Diseases

在研机构

Crucell Holdings, Inc.

Program for Appropriate Technology in HealthNational Institute of Allergy & Infectious Diseases

+ [1]

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Malaria vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床试验

NCT04327440 / Unknown statusN/AIIT

Combined Effects of RTS,S Vaccination and PBO Nets on Malaria Infection and Transmission in Malawi

The overall goal of this study is to assess the impact of RTS,S (malaria) vaccination and PBO nets on malaria infection and transmission, independently and how they interact when they are introduced together.
The specific objectives for the study are as follows:
1. To estimate the impact of PBO nets and RTS,S vaccine on Plasmodium infection prevalence and transmission, independently and how they interact when they are introduced together in Malawi (Phase 1).
2. To assess the feasibility of evaluating the impact of RTS,S vaccine and PBO nets independently in a larger scale future study.

开始日期2020-02-04

申办/合作机构

Michigan State University

[+3]

EUCTR2019-002872-14-GB / Unknown status临床1/2期IIT

A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK - VAC079: Safety and efficacy of the PvDBPII in Matrix M1 vaccine

开始日期2019-11-12

申办/合作机构-

100 项与 Malaria vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床结果

登录后查看更多信息

100 项与 Malaria vaccine(National Institute of Allergy & Infectious Diseases) 相关的转化医学

登录后查看更多信息

100 项与 Malaria vaccine(National Institute of Allergy & Infectious Diseases) 相关的专利（医药）

登录后查看更多信息

150

项与 Malaria vaccine(National Institute of Allergy & Infectious Diseases) 相关的文献（医药）

2024-12-31·Human Vaccines & Immunotherapeutics

A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health

Review

作者: Alanzi, Abeer ; Shrwani, Reem ; Albalawi, Reem ; Marghlani, Lujain ; Saad, Abrar ; Althobaiti, Khaled ; Al-Osaimi, Hind M. ; Alasmari, Saba ; Alsofiyani, Razan ; Al-Rowaili, Badria ; Alhulaili, Zainab ; Alqarni, Rawan ; Kanan, Mohammed

Insect vector-borne diseases (VBDs) pose significant global health challenges, particularly in tropical and subtropical regions. The WHO has launched the "Global Vector Control Response (GVCR) 2017-2030" to address these diseases, emphasizing a comprehensive approach to vector control. This systematic review investigates the potential of malaria and dengue vaccines in controlling mosquito-borne VBDs, aiming to alleviate disease burdens and enhance public health. Following PRISMA 2020 guidelines, the review incorporated 39 new studies out of 934 identified records. It encompasses various studies assessing malaria and dengue vaccines, emphasizing the significance of vaccination as a preventive measure. The findings indicate variations in vaccine efficacy, duration of protection, and safety considerations for each disease, influencing public health strategies. The review underscores the urgent need for vaccines to combat the increasing burden of VBDs like malaria and dengue, advocating for ongoing research and investment in vaccine development.

2024-12-01·Nature Reviews Microbiology

Malaria vaccines: a new era of prevention and control

Review

作者: Healy, Sara A ; Duffy, Patrick E ; Fried, Michal ; Gorres, J Patrick

Malaria killed over 600,000 people in 2022, a death toll that has not improved since 2015. Additionally, parasites and mosquitoes resistant to existing interventions are spreading across Africa and other regions. Vaccines offer hope to reduce the mortality burden: the first licensed malaria vaccines, RTS,S and R21, will be widely deployed in 2024 and should substantially reduce childhood deaths. In this Review, we provide an overview of the malaria problem and the Plasmodium parasite, then describe the RTS,S and R21 vaccines (the first vaccines for any human parasitic disease), summarizing their benefits and limitations. We explore next-generation vaccines designed using new knowledge of malaria pathogenesis and protective immunity, which incorporate antigens and platforms to elicit effective immune responses against different parasite stages in human or mosquito hosts. We describe a decision-making process that prioritizes malaria vaccine candidates for development in a resource-constrained environment. Future vaccines might improve upon the protective efficacy of RTS,S or R21 for children, or address the wider malaria scourge by preventing pregnancy malaria, reducing the burden of Plasmodium vivax or accelerating malaria elimination.

2024-12-01·Vaccine

RTS, S malaria vaccination among children aged 24–59 months in the Sunyani Municipality, Ghana; 2023

Article

作者: Kubio, Chrysantus ; Tamal, Christopher Sunkwa ; Adjei, Michael Rockson ; Kyeremeh, Richard Adinkrah ; Ziema, Sorengmen Amos ; Abanga, Williams Azumah ; Zacharia, Mansulu Mohammed

BACKGROUNDFollowing the successful pilot of RTS,S malaria vaccine, it has been recommended by the WHO for prevention of Plasmodium falciparum malaria in children living in endemic areas. Despite the proven benefits of the malaria vaccine, uptake especially of the fourth dose, remains relatively low. We assessed complete uptake of RTS,S malaria vaccine among children 24-59 months and associated factors in the Sunyani Municipality of Ghana.METHODSA cross-sectional study was conducted among 361 caregivers of children aged 24-59 months in the Sunyani Municipality, who had received at least one dose of RTS,S malaria vaccine. Structured questionnaires were administered to caregivers and relevant vaccination information was extracted from the maternal and child health record books. Binary logistic regression analysis was used to determine factors associated with complete uptake of the vaccine at 95 % confidence interval (CI).RESULTSApproximately 45 % (164/361) of the children had completed the RTS,S malaria vaccination schedule. Children aged 48-59 months (AOR:0.26, 95 %CI:0.09-0.76), those with caregivers who believed that children were being used for experiment (AOR:0.29, 95 %CI:0.16-0.54) or doubted the safety of the vaccine (AOR:0.27, 95 %CI:0.14-0.52) were less likely to complete the four doses. On the other hand, children of caregivers who reported vaccine shortages and travelled long distances to access immunization services (AOR:3.15, 95 %CI:1.17-8.47), and those with adequate knowledge on the malaria vaccine (AOR:1.89, 95 %CI:1.08-3.29) were more likely to complete the vaccination schedule.CONCLUSIONLess than half of the children who started RTS,S malaria vaccination completed the full schedule. Age of child, caregiver knowledge and perception of the malaria vaccine, and access to immunization service were associated with complete uptake of the RTS,S malaria vaccine. Strengthening caregiver education and access to immunization services could improve uptake of the subsequent doses and coverage of the fourth dose.

100 项与 Malaria vaccine(National Institute of Allergy & Infectious Diseases) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Malaria vaccine(National Institute of Allergy & Infectious Diseases)	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疟疾	临床1期	-	National Institute of Allergy & Infectious Diseases	-
疟疾	临床1期	-	Program for Appropriate Technology in Health	-
疟疾	临床1期	-	Novavax, Inc.	-
疟疾	临床1期	-	Crucell Holdings, Inc.	-